



Protocols for Laboratory Verification of Performance of the BioFire® Blood Culture Identification 2 (BCID2) Panel

Laboratory Protocols for Use with a ZeptoMetrix NATtrol™ Verification Panel

Purpose

The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory testing to ensure the accuracy and reliability of patient test results, regardless of where the test is performed. The CLIA regulations include a requirement for verifying the performance specifications of unmodified, moderate complexity tests cleared or approved by the FDA.

This document provides an example of a verification procedure to assist your laboratory in developing a protocol for the verification of the BioFire BCID2 Panel performance on BioFire FilmArray® Systems as required by CLIA. A verification scheme, compatible with the BioFire BCID2 Panel, has been designed using nonclinical specimens. This scheme provides positive and negative tests for each organism detected by the BioFire BCID2 Panel and may be easily modified or expanded to meet specific criteria. Day-to-day variation is evaluated by testing each sample on two separate days. To evaluate user-to-user variation, multiple laboratory technicians may test the same sample. In addition, testing patient samples for verification of the performance of the BioFire BCID2 Panel should be done under the guidance of the Laboratory Director but is not described here.

As per the CLIA regulation, the Laboratory Director is ultimately responsible for ensuring that verification procedures meet the appropriate standards for CLIA and applicable laboratory accrediting agencies.

BioFire Intended Use

The BioFire BCID2 Panel is a multiplexed nucleic acid test intended for use with BioFire® FilmArray® 2.0 or BioFire® FilmArray® Torch Systems for the simultaneous qualitative detection and identification of multiple bacterial and yeast nucleic acids and select genetic determinants associated with antimicrobial resistance. The BioFire BCID2 Panel test is performed directly on blood culture samples identified as positive by a continuous monitoring blood culture system. Results are intended to be interpreted in conjunction with Gram stain results. The following organism types and subtypes are identified using the BioFire BCID2 Panel:







	Gram Positive Bacteria	
Enterococcus faecalis	Staphylococcus spp.	Streptococcus spp.
Enterococcus faecium	Staphylococcus aureus	Streptococcus agalactiae (Group B)
Listeria monocytogenes	Staphylococcus epidermidis	Streptococcus pneumoniae
	Staphylococcus lugdunensis	Streptococcus pyogenes (Group A)
	Gram Negative Bacteria	
Acinetobacter calcoaceticus-baumannii complex		Enterobacterales
Bacteroides fragilis		Enterobacter cloacae complex
Haemophilus influenzae		Escherichia coli
Neisseria meningitidis (encapsulated)		Klebsiella aerogenes
Pseudomonas aeruginosa		Klebsiella oxytoca
Stenotrophomonas maltophilia		Klebsiella pneumoniae group
		Proteus spp.
		Salmonella spp.
		Serratia marcescens
	Yeast	
Candida albicans	Candida krusei	Cryptococcus neoformans/gattii
Candida auris	Candida parapsilosis	
Candida glabrata	Candida tropicalis	

The BioFire BCID2 Panel contains assays for the detection of genetic determinants associated with resistance to methicillin (*mecA/C* and *mecA/C* in conjunction with MREJ), vancomycin (*vanA* and *vanB*), β-lactams including penicillins, cephalosporins, monobactams, and carbapenems (*bla*_{CTX-M}, *bla*_{IMP}, *bla*_{KPC}, *bla*_{NDM}, *bla*_{OXA48-like}, *bla*_{VIM}) to aid in the identification of potentially antimicrobial-resistant organisms in positive blood culture samples. In addition, the panel includes an assay for the detection of the mobilized genetic determinant *mcr-1*, an emerging marker of public health importance. The antimicrobial resistance gene or marker detected may or may not be associated with the agent responsible for disease. Negative results for these select antimicrobial resistance gene and marker assays do not indicate susceptibility, as multiple mechanisms of resistance to methicillin, vancomycin, β-lactams, and colistin exist.

		Antimicrobial Resistance Genes	i e	
CTX-M	KPC	mecA/C	NDM	vanA/B
IMP	mcr-1	mecA/C and MREJ (MRSA)	OXA-48-like	VIM

The complete intended use statement and additional information about the use of the BioFire System can be found in the *BioFire® Blood Culture Identification 2 (BCID2) Panel Instructions for Use.*





Performance Verification: Overview

Two different examples of performance verification procedures are described: (1) a Simple Protocol for the verification of the BioFire BCID2 Panel performance and (2) a Blood Culture Media Protocol that evaluates the BioFire BCID2 Panel performance when organisms are in a blood culture media sample matrix. These protocols are examples of procedures to assist your laboratory in developing a protocol for the verification of BioFire BCID2 Panel performance on BioFire Systems.

The verification procedures described here may be used to evaluate the performance of each assay on the BioFire BCID2 Panel. The performance verification protocols have been designed to take advantage of the multiplex nature of the BioFire BCID2 Panel. Verification testing efficiency is maximized by evaluating multiple target organisms in a single test run. The procedures described below will generate multiple positive and negative detections for each of the BioFire BCID2 assays. The procedures were developed using a BCID2 Verification Panel available from ZeptoMetrix LLC, Buffalo, NY (part number NATBCP2-BIO).

A BioFire System is defined as all BioFire® FilmArray® Instruments or Modules that are connected to and controlled by a single computer system. If the laboratory director chooses not to perform the entire verification protocol on each individual instrument, it is advised that test replicates are evenly distributed among the instruments or modules. An example of a performance verification workflow using 2, 4, or 6 modules is provided in Figure 2.

Clinical/patient samples may be used in place of, or in addition to the verification schemes described here in order to assess clinical sensitivity/specificity and sample matrix effects as part of the performance verification of the BioFire BCID2 Panel.

Table 1. Overview of Verification Protocol

Verification Protocol	Organisms per Pool	Number of Sample Pools	Replicates per Sample Pool	Pouches Required	Expected Positive Results ^a	Expected Negative Results	Approximate Days of Testing ^b
Example 1: Simple Protocol	6 or 7	5	4	20	≥4 per organism	12-16 per organism	4
Example 2: Blood Culture Media Protocol	6 or 7	5	4	20	≥4 per organism	12-16 per organism	4

^a The expected number of positives and negatives per organism is dependent upon the number strains of a particular organism used to complete the verification. The proposed verification procedure recommends multiple *K. pneumoniae* strains; therefore, the number of expected *K. pneumoniae* group positives would be 8 and the number of expected negatives would be 12.



^b The approximate number of days for testing assumes a BioFire*system configured with one instrument/module.



Performance Verification: Materials

The following materials may be used to perform the verification procedure:

Table 2. Recommended materials for the verification protocols:

Material	Part Number
BioFire® Blood Culture Identification 2 (BCID2) Panel (30-test kit)	BioFire Diagnostics, LLC RFIT-ASY-0147
BioFire® Blood Culture Identification 2 (BCID2) Panel Instructions for Use	BioFire Diagnostics, LLC RFIT-PRT-0841
BioFire® Blood Culture Identification 2 (BCID2) Panel Quick Guide	BioFire Diagnostics, LLC RFIT-PRT-0867
Blood culture media ^a	BACT/ALERT® FA PLUS , 410851 ^a (or equivalent)
Control Organism ^b	ZeptoMetrix NATBCP2-BIO
2 mL or 5 mL Sample Tubes	Various manufacturers
Polystyrene tubes with cap (15 mL)	VWR, 82050-278 (or equivalent)
10-mL syringe and 18 gauge needle	VWR, 75846-756 and BD-305196 (or equivalent)
Serological pipette, 5 mL	VWR, 82050-478 (or equivalent)
Disposable Transfer pipets, graduated	VWR, 414004-024 (or equivalent)

^a SeeTable 84 in the BioFire® Blood Culture Identification 2 (BCID2) Panel Instructions for Use for other compatible blood culture bottle types.

The BioFire BCID2 Panel contains assays for the detection of genetic determinants of resistance, including the mobilized colistin resistance gene 1 (*mcr-1*). The NATBCP2-BIO contains inactivated organisms and materials of human and animal origin. Safe practices suggest that the product be considered potentially infectious and to use universal precautions when handling. Refer to local laboratory guidelines for proper handling and disposal guidelines. More information can be found in the *BioFire® Blood Culture Identification 2* (*BCID2*) Panel Instructions for Use and on the Center for Disease Control and Preventions (CDC) website:

Standard and Contact Precautions: https://www.cdc.gov/hicpac/2007IP/2007ip_part3.htm Infection control guidelines:

https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html#a4



^bAny appropriate source of organism may be used for verification of any or all of the assays in the BioFire BCID2 Panel. However, when alternate organism sources are used (i.e. not the ZeptoMetrix NATBCP2-BIO material), the sample volumes or pooling schemes suggested in the examples below may need to be adjusted.



Performance Verification Protocols

Simple Protocol

The Simple Protocol evaluates the BioFire BCID2 Panel performance when sample material (ZeptoMetrix NATBCP2-BIO) is pooled in the absence of clinical matrix. The proposed organism pooling scheme (Table 3) should be followed to obtain the expected number of positive and negative results for each assay in a time and resource-efficient manner.

Note: Dilution of ZeptoMetrix BCID2 Verification Panel organisms beyond levels proposed in these guidelines may lead to inconsistent results and is not recommended.

The Simple Protocol and workflow schemes (Figures 1 and 2) illustrate testing 4 replicates per pool for 5 pools over multiple days. This produces a total of 20 verification sample test runs and provides at least 4 positive results and as many as 16 negative results per assay. Some organisms, such as *Klebsiella pneumoniae*, are represented multiple times. This is done to ensure all antimicrobial resistance genes are represented in the verification protocol.

The number of samples tested per day should be determined by the individual laboratory. This testing scheme can be modified to run more samples per day based on the number of modules in the BioFire System. The pooling scheme provides sufficient volume for testing more replicates if desired.

Pooled samples can be stored overnight (or up to 3 days) at refrigeration temperature (2–8°C) for subsequent testing to evaluate day-to-day variation.

Table 3. Proposed Organism Pooling Scheme for Simple Protocol

Organism and Resistance Genes	Approximate Organism Volume	Approximate Pool Volume
Pool 1		
Acinetobacter baumannii	0.2 mL	
Candida albicans	0.2 mL	
Enterococcus faecalis (vanB)	0.2 mL	
Enterococcus faecium (vanA)	0.2 mL	1.4 mL
Staphylococcus aureus (mecA and MREJ)	0.2 mL	
Streptococcus agalactiae	0.2 mL	
Streptococcus pyogenes	0.2 mL	
Pool 2		
Candida glabrata	0.2 mL	
Candida krusei	0.2 mL	
Enterobacter cloacae	0.2 mL	
Haemophilus influenzae	0.2 mL	1.4 mL
Klebsiella oxytoca	0.2 mL	
Listeria monocytogenes	0.2 mL	
Staphylococcus epidermidis	0.2 mL	







Pool 3		
Bacteroides fragilis	0.2 mL	
Candida parapsilosis	0.2 mL	
Candida tropicalis	0.2 mL	
Klebsiella pneumoniae (KPC)	0.2 mL	1.4 mL
Pseudomonas aeruginosa (VIM)	0.2 mL	
Serratia marcescens	0.2 mL	
Streptococcus pneumoniae	0.2 mL	
Pool 4		
Candida auris	0.2 mL	
Escherichia coli Z521 (mcr-1)	0.2 mL	
Escherichia coli Z297 (IMP)	0.2 mL	
Klebsiella aerogenes	0.2 mL	1.4 mL
Neisseria meningitidis	0.2 mL	
Proteus mirabilis	0.2 mL	
Stenotrophomonas maltophilia	0.2 mL	
Pool 5		
Cryptococcus gattii	0.2 mL	
Cryptococcus neoformans	0.2 mL	
Klebsiella pneumoniae Z138 (CTX-M and OXA-48 like)	0.2 mL	1.2 ml
Klebsiella pneumoniae Z460 (CTX-M and NDM)	0.2 mL	1.2 111
Salmonella enterica typhimurium	0.2 mL	
Staphylococcus lugdunensis	0.2 mL	

Simple Protocol Example

The estimated total time for completion for this Simple Protocol verification example is 4 days for a BioFire System configured with 1 module. A proposed organism pooling scheme is presented above in Table 3. Figure 1 illustrates a simplified workflow schematic. The number of samples tested per day should be determined by the individual laboratory. The protocol can be modified to run more samples per day (or fewer) based upon the number of modules in the BioFire System. The proposed organism pooling scheme in Table 3 provides sufficient volume for testing more replicates, if desired. Figure 2 provides an examples of user-to-user, day-to-day, and module-to-module testing for labs with multiple BioFire Modules.

Note: It is important to prepare only the number of sample pools that will be tested within 3 days of preparation. The suggestion to prepare 3 sample pools is based on testing up to 6 pouches per day. The number of samples prepared may be increased or decreased based on the laboratory's work schedule and number of modules connected within a BioFire System.

Day 1

- 1. Organize materials needed (Table 2).
- 2. Prepare three sample pools (i.e. Pools #1, 2, and 3) from ZeptoMetrix NATBCP2-BIO control material. Organism vials should be well mixed prior to preparing each pool. Refer to Table 3 for example organism pooling schemes and specific volumes for each pool.





- a. Transfer the entire contents of the ZeptoMetrix organism vial (approximately 0.2 mL) into a 2 mL tube. Alternatively, a 5mL tube may be used.
- b. Repeat with the second (and subsequent) organisms to combine the appropriate organisms for each pool into a single tube (approximately 1.4 mL total volume for pools 1-4 or 1.2 mL for pool 5).
- c. Ensure the pooled sample is well mixed prior to removing a sample for testing.
- 3. Repeat Step 2 for the remaining sample pools (i.e. Pool #2) to be prepared on Day 1.
- 4. Test 2 replicates from a single sample pool (i.e. Figure 1: Pool # 1 replicates A and B). The replicate samples should be tested in a single day by different users.

Note: For each sample, follow instructions in the BioFire® Blood Culture Identification 2 (BCID2) Panel Instruction Booklet and BioFire® Blood Culture Identification 2 (BCID2) Panel Quick Guide for pouch preparation, pouch hydration, sample loading, and sample testing.

- 5. Repeat Step 4 for the remaining sample pool replicates to be tested that day (i.e. Pool # 2 replicates A and B)
- 6. Refrigerate samples (2–8°C) for up to 3 days for the evaluation of day-to-day variation.

Note: The proposed organism pooling scheme (Table 3) provides sufficient material for running samples as described in Figure. 1. The volume is sufficient for testing more samples if desired.

Day 2

To evaluate day-to-day variation, test replicates from the same sample pools prepared on Day 1 by repeating Step 4 above (i.e. Pool # 1 replicates C and D).

Day 3

Prepare 2 new sample pools (i.e. pools #4 and 5) as described in Steps 2-3. Test replicates as described in Step 4 above.

Day 4

To evaluate day-to-day variation, test replicates from the same sample pools prepared on Day 3 by repeating Step 4 above (i.e. Pool # 4 replicates C and D).

Note: Extreme care should be used in properly handling and disposing of organisms containing antibiotic resistance genes. Follow your institution's guidelines for proper handling and disposal of pathogens or refer to the CDC Infection control guidelines:

https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html#a4

Figure 1. Workflow for the Simplified or the Blood Culture Media Protocols








Figure 2. Example of a Verification workflow for use with multiple BioFire Modules

2 Modules		Module 1			Module 2	
Day 1	Pool 1/ User 1	Pool 2/ User 2	Pool 3 / User 1	Pool 1/ User 2	Pool 2/ User 1	Pool 3/ User 2
Day 2	Pool 1/ User 2	Pool 2/ User 1	Pool 3/ User 2	Pool 1/ User 1	Pool 2/ User 2	Pool 3 / User1
Day 3	Pool 4 / User 1	Pool 5 / User 2		Pool 4 / User	Pool 5 / User	
Day 3	Pool 4 / User 2	Pool 5 / User 1		Pool 4 / User	Pool 5 / User 2	





4 Modules	Mod	ule 1	Mod	ule 2	Mod	ule 3	Mod	ule 4
	D 14/	D 101		D 10/	Pool 3		D 10/	
	Pool 1/	Pool 2/	Pool 1/	Pool 2/	/ User		Pool 3/	
Day 1	User 1	User 2	User 2	User 1	1		User 2	
	Pool 3/		Pool 3/		Pool 1/	Pool 2/	Pool 1/	Pool 2/
Day 2	User1		User 2		User 1	User 2	User 2	User 1
					Pool 5		Pool 5	
	Pool 4/		Pool 4/		/ User		/ User	
Day 3	User 1		User 2		2		1	
					Pool 4		Pool 4	
	Pool 5 /		Pool 5 /		/ User		/ User	
Day 4	User 1		User 2		1		2	

6 Modules	Module 1	Module 2	Module 3	Module 4	Module 5	Module 6
Down	Pool 1/	Pool 1/	Pool 2/	Pool 2/	Pool 3 / User	Pool 3/
Day 1 Day 2	User 1 Pool 3/ User 2	User 2 Pool 3 / User1	User 1 Pool 1/ User 2	User 2 Pool 1/ User 1	Pool 2/ User 2	User 2 Pool 2/ User 1
Day 2	USCI Z	USCIT	Pool 4/	Pool 4 / User	Pool 5 / User	Pool 5 / User
Day 3			User 1	2	1 Pool 4	2
Day 4	Pool 5 / User 1	Pool 4 / User 2	Pool 5 / User 2		/ User 1	

Blood Culture Media Protocol

The Blood Culture Media Protocol evaluates the BioFire BCID2 Panel performance when sample material (ZeptoMetrix NATBCP2-BIO) is pooled in the presence of clinical matrix. The proposed organism pooling scheme (Table 4) should be followed to obtain the expected number of positive and negative results for each assay in a time and resource-efficient manner.

Note: Dilution of organisms beyond levels proposed in these guidelines may lead to inconsistent results and is not recommended.

Figures 1 and 2 (above) illustrate protocol and workflow schemes for testing 4 replicates per pool for 5 pools over multiple days. This produces a total of 20 verification sample test runs and provides at least 4 positive results and as many as 16 negative results per assay. Some organisms, such as *Klebsiella pneumoniae*, are represented multiple times. This is done to ensure all antimicrobial resistance genes are represented in the verification protocol.

The number of samples tested per day should be determined by the individual laboratory. This testing scheme can be modified to run more samples per day based on the number of





modules in the BioFire®System. The pooling scheme provides sufficient volume for testing more replicates if desired.

Pooled samples can be stored overnight (or up to 3 days) at refrigeration temperature (2–8°C) for subsequent testing to evaluate day-to-day variation.

Table 4. Proposed Organism Pooling Scheme for the Blood Culture Media Sample Matrix Protocol

Organism and Resistance Genes	Approximate Organism Volume	Volume of Blood Culture Medium	Approximate Final Pool Volume
Pool 1			
Acinetobacter baumannii	0.2 mL		
Candida albicans	0.2 mL		
Enterococcus faecalis (vanB)	0.2 mL		
Enterococcus faecium (vanA)	0.2 mL	1.4 mL	2.8 mL
Staphylococcus aureus (mecA and MREJ)	0.2 mL		
Streptococcus agalactiae	0.2 mL		
Streptococcus pyogenes	0.2 mL		
Pool 2			
Candida glabrata	0.2 mL		
Candida krusei	0.2 mL		
Enterobacter cloacae	0.2 mL		
Haemophilus influenzae	0.2 mL	1.4 mL	2.8 mL
Klebsiella oxytoca	0.2 mL		
Listeria monocytogenes	0.2 mL		
Staphylococcus epidermidis	0.2 mL		
Pool 3			
Bacteroides fragilis	0.2 mL		
Candida parapsilosis	0.2 mL		
Candida tropicalis	0.2 mL		
Klebsiella pneumoniae (KPC)	0.2 mL	1.4 mL	2.8 mL
Pseudomonas aeruginosa (VIM)	0.2 mL		
Serratia marcescens	0.2 mL		
Streptococcus pneumoniae	0.2 mL		
Pool 4			
Candida auris	0.2 mL		
Escherichia coli Z521 (mcr-1)	0.2 mL		
Escherichia coli Z297 (IMP)	0.2 mL		
Klebsiella aerogenes	0.2 mL	1.4 mL	2.8 mL
Neisseria meningitidis	0.2 mL		
Proteus mirabilis	0.2 mL		
Stenotrophomonas maltophilia	0.2 mL		







Pool 5			
Cryptococcus gattii	0.2 mL		
Cryptococcus neoformans	0.2 mL		
Klebsiella pneumoniae Z138 (CTX-M and OXA-48 like)	0.2 mL	1.2 mL	2.4 mL
Klebsiella pneumoniae Z460 (CTX-M and NDM)	0.2 mL	1.2 ML	2.4 ML
Salmonella enterica typhimurium	0.2 mL		
Staphylococcus lugdunensis	0.2 mL		

Blood Culture Media Protocol Example

The estimated total time for completion for this Blood Culture Media Protocol verification example is 4 days for a BioFire System configured with 1 module. A proposed organism pooling scheme is presented above in Table 4. Figure 1 illustrates a simplified workflow schematic. The number of samples tested per day should be determined by the individual laboratory. The protocol can be modified to run more samples per day (or fewer) based upon the number of modules in the BioFire System. The proposed organism pooling scheme in Table 4 provides sufficient volume for testing more replicates, if desired. Figure 2 provides an examples of user-to-user, day-to-day, and module-to-module testing for labs with multiple BioFire Modules.

Note: It is important to prepare only the number of sample pools that will be tested within 3 days of preparation. The suggestion to prepare 3 sample pools is based on testing up to 6 pouches per day. The number of samples prepared may be increased or decreased based on the laboratory's work schedule and number of modules connected within a BioFire System.

Pooled samples may be stored overnight (or up to 3 days) at refrigeration temperature (2–8°C) for subsequent testing to evaluate day-to-day variation. To evaluate user-to-user variation, multiple laboratory technicians may perform testing.

Day 1

- 1. Organize materials needed (Table 2).
- 2. Prepare three sample pools (i.e. Pools #1, 2, and 3) from ZeptoMetrix NATBCP2-BIO. Organism vials should be well mixed prior to preparing each pool. Refer to Table 3 for example organism pooling schemes and specific volumes for each pool.
 - a. Use a 10-mL syringe and an 18 gauge needle to remove approximately 8 mL of blood culture medium from a blood culture bottle and transfer it to a 15mL tube. Care should be taken to minimize transferring resin beads into the sample.
 - b. Use a serological pipette to add 1.2 or 1.4 mL of blood culture media (as described in Table 4) into a sterile 5 mL tube.
 - c. Transfer the entire contents of the ZeptoMetrix organism vial (approximately 0.2 mL) into the 5 mL tube containing blood culture media.





- d. Repeat for the remaining organisms in the pool to combine the appropriate organisms into a single tube.
- e. Ensure the pooled sample is effectively mixed prior to removing a sample for testing.
- 3. Repeat Step 2 for the remaining sample pools (i.e. Pool #2) to be prepared on Day 1.
- 4. Test 2 replicates from a single sample pool (i.e. Figure 1: Pool # 1 replicates A and B). The replicate samples should be tested in a single day by different users.

Note: For each sample, follow instructions in the BioFire® Blood Culture Identification 2 (BCID2) Panel Instruction Booklet and BioFire® Blood Culture Identification 2 (BCID2) Panel Quick Guide for pouch preparation, pouch hydration, sample loading, and sample testing.

- 5. Repeat Step 4 for the remaining sample pool replicates to be tested that day (i.e. Pool # 2 replicates A and B)
- 6. Refrigerate samples (2–8°C) for up to 3 days for the evaluation of day-to-day variation.

Note: The proposed organism pooling scheme (Table 3) provides sufficient material for running samples as described in Figure. 1. The volume is sufficient for testing more samples if desired.

Day 2

To evaluate day-to-day variation, test replicates from the same sample pools prepared on Day 1 by repeating Step 4 above (i.e. Pool # 1 replicates C and D).

Day 3

Prepare 2 new sample pools (i.e. pools #4 and 5) as described in Steps 2-3. Test replicates as described in Step 4 above.

Day 4

To evaluate day-to-day variation, test replicates from the same sample pools prepared on Day 3 by repeating Step 4 above (i.e. Pool # 4 replicates C and D).

Note: Extreme care should be used in properly handling and disposing of organisms containing antibiotic resistance genes. Follow your institution's guidelines for proper handling and disposal of pathogens or refer to the CDC Infection control guidelines:

https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html#a4





Expanding the protocols

The protocols described above can be expanded by increasing the number of tests from each of the organism pools. Each organism pool contains sufficient volume for testing additional replicates.

Verification of Loaner, Repaired, and Permanent Replacement Instruments

If it becomes necessary to verify the performance of a loaner, repaired, or permanent replacement instrument, the following protocol may serve as a guideline but should be verified by the Laboratory Director.

- Select a few specimens and/or proficiency samples (any combination of positives and negatives) previously tested on the BioFire BCID2 Panel. The Laboratory Director should determine the appropriate number of samples to test. Proficiency samples should not be pooled or diluted.
- 2. Select a set of controls that verify detection of all targets on the BioFire BCID2 Panel.
- 3. Test the selected samples on the loaner, repaired, or permanent replacement instrument and document the results.

Technical Support Contact Information

BioFire is dedicated to providing the best customer support available. If you have any questions or concerns about this process, please contact the BioFire Technical Support team for assistance.

BioFire Technical Support Email: support@biofiredx.com

Phone: +1-801-736-6354, select Option 5

All product names, trademarks and registered trademarks are property of their respective owners.





BioFire® Blood Culture Identification 2 (BCID2) Panel Verification Record

Opposition and feetstaring Ones. Opposition and feetstaring Ones. \$ 4 4 4 5 5 5 Problem of the control of complex. \$ 4 4 4 5 5 5 Problem of the control of complex. \$ 4 4 4 5 5 5 Problem of the control of complex. \$ 4 4 4 5 5 5 Problem of the control of complex. \$ 5 5 5 5 5 5 5 5 5 5 \$ 5 5 5 5 5 5 5 Problem of the control of complex. \$ 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	BioFire® Blood Culture Identification 2 (BCID2) Panel Kit Part #) Panel		ž Š	Module Serial #	erial #				Ĕ	Module Serial #	erial #					Module Serial #	Seria	# #				ı
Comparison of Contest				[5											ı
Continue and Assistance Continue Continue and Assistance and Assistance Continue and Assistance and Assista								Rep	licate T	Testing										S	ummar	^	
Accordation between carbonate demonstrate the control of the con	Organism and Resistance Genes		D-I				0-7	A-8	8-8	D-8						8-8	2-0	Q-9					
Entercoccus feeding feeds	Acinetobacter calcoaceticus-baumannii complex																			_	-	_	
Entercoccus faecalis (aneB) Entercoccus faecalis (aneB)	Candida albicans																						
Staphylococcus aurass (meck and MREJ) Staphylococcus agailactive Straphococcus agailactive Straphococcus agailactive Straphococcus agailactive Straphococcus agailactive Straphococcus agailactive Straphococcus agailactive Candida pubma Candida butae Evaluation Straphococcus agailactive Straphylococcus agailact	Enterococcus faecalis (vanB)																						
Statishylococcus againcties																							
Streptococcus againecties Streptococcus preumonies group St																							
Streichtcoccus progenes																							
The control of the Earl (MRSA)	Streptococcus pyogenes																						_
Candida galanta	mecA/C and MREJ (MRSA)				-						1												+
Candida krusical candida conse complex. Candida krusical candida paesis candida cantida paesis candida candida cantida paesis candida cantida candida cantida paesis candida cantida paesis candida cantida cantida cantida candida cantida c	vanA/B		1	+			I			-	+	-	-	_	1		T			-	-	-	-
Cardida kusel Entercalce complex Entercalce complex Entercalce complex Relabsiella oxytoca Listeria monocytogenes Staphylococcus epidemidis Bacteroides fragilis Cardida trapicals Cardida trapicals Sendida aurosecens Sendi	Candida glabrata																						-
Entertractactor clocace oromplex Entertractactor clocace oromplex Hearnophilus influences	Candida krusei																						
Heemophilus influenzae																							
						_					+												-
Listeria monocytogeness Staphylococous gaidermidis											+	-	4									_	-
Stabhylococcus apidemidis Bacteroides tragilis Bacteroides tragilis Bacteroides registics Candida projections Serratia marcascens Streptococcus preumoniae KPC VIM Candida auris Streptococcus preumoniae KPC VIM Candida auris Streptococcus preumoniae Streptococcus preumoniae KPC VIM Candida auris Esofrarichia coli Es	Listeria monocytogenes										+	-	4									_	-
Candida parapaliosis Candida parapaliosis	Staphylococcus epidermidis			\dashv	\dashv	\downarrow					+	-	4						-		_		-
In a preumoniae group KPC In a paraps/losis In a preumoniae group KPC In a auris In a preumoniae group In a pr	Bacteroides fragilis																						-
Candida trapicalis KPC Rebsiella preumoniae group KPC Pseudomonas aeruginosa VIM Serratia marcescens Straptococcus preumoniae KPC XPC VIM ZE21 (mcr.1) Candida auris ZE21 (mcr.1) Escherichia coli ZE21 (mcr.1) Klabsiella aerogenes Nelsseria meningtidis (encapsulated) Nelsseria meningtidis (encapsulated) Nelsseria meningtidis (encapsulated) Alesseria	Candida parapsilosis																						
Klebs sella preumoniae group KPC Pseudomonas aeruginosa VIM Serratia marcescens Straptococcus preumoniae KPC XIM VIM Cardida auris Escherichia coli ZE21 (mcr.1) Klabsiella aerogenes Klabsiella aerogenes Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Melsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Sterotrochromonas maltophilira Nelsseria meringtidis (encapsulated) Roychococcus neoformans/gattifi OXA-48 like Ariante spp. Zido (CTX-M and Zido) Salmonella spp. Zido (CTX-M and Zido) Salmonella spp. Zido (CTX-M and Zido) OXA-48 like NDM OXA-48 like NBM OXA-48 like NBM																							
Pseudomonas aeruginosa VIM Serratia marcescens Serratia marcescens Streptococcus preumoniae EZZ1 (mcr-1) KPC ZZ21 (mcr-1) VIM ZZ21 (mcr-1) Candida auris ZZ21 (mcr-1) Escherichia coli ZZ21 (mcr-1) Klabsiella aerogenes Notabilia Robisenia meningitidis (encapsulated) Notabilia Proteus spp. Sterotrophomonas maltophilia MAP OXA-48 like) Cypticococcus neoformans/gattif OXA-48 like Cypticococcus neoformans/gattif Salmonella spp. Salmonella spp. Z450 (CTX-M and Z450 (CTX-M and Z450 (CTX-M and Z450 (CTX-M and NDM) NDM NDM NDM OXA-48 like Reviewed by: Reviewed by:																							
Serration marcoscens Serration KPC KPC VIM Candida auris Candida auris Escherichia coli Escherichia coli ZE21 (mcr.1) Klabsiella aerogenes Klabsiella derogenes Alesseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Nelsseria meringtidis (encapsulated) Netoriococcus neoformans/gattii Cyptrococcus neoformans/gattii Cyptrococcus neoformans/gattii Cyptrococcus neoformans/gattii Cyptrococcus neoformans/gattii DXA-48 like Salmonella spp. Z460 (CTX-M and Salmon) Staphylococcus lugdunensis CTX-M NDM NDM OXA-48 like NDM OXA-48 like NDM OXA-48 like NBM										+													4
KPC KPC VIM Cardida auris Candida auris Escherichia coli Escherichia coli Zaz1 (mcr-1) Escherichia coli Zaz1 (mcr-1) Klabsialia aerogenes Riesseria menirgitidis (encapsulated) Nelsseria menirgitidis (encapsulated) Sterotrophomoras maltophilia NRP Cryptococcus neoformans/gattii Cryptococcus neoformans/gattii CX-48 like) Klebsiella pneumoniae group ZuGo (CTX-M and Salmonella spp. Salmonella spp. ZuGo (CTX-M and Salmonella spp. Staphylococcus lugdunersis CTX-M NDM NDM NDM NDM OXA-48 like CTX-M and Salmonella spp.	Serratia marcescens																						
Content Cont	Streptococcus pneumoniae																						
Contain Cont	KPC																						
Chie coli Annual Carl (mcr-1) Carl (mcr-1) Carl (mcr-1) Carl (mcr-1) Carl (mr-1) Carl	VIM								1	\dashv	4									_	-	4	4
Circle coli Circle Circl																							
Neisseria meningitidis (encapsulated) (Edisseria meningitidis (encapsulated)) Porteuss spp. Stenotrophomonas maltophilia IMP (Edisperimental processor in the processor is a processor in the processor																							
Sepp.																							
Stenotrophomorias maltophilia Stenotrophomorias maltophilia Stenotrophomorias maltophilia Stenotrophomorias maltophilia Stenotrophomorias maltophilia Cryptococcus neoformans/gatti Cryptococcus neoformans/gatti Cryc.M and Cryptococcus lugdunersis Cryc.M and Cryc.M and Cryc.M and Cryc.M and Cryc.M and Cryc.M NDM ND	Neisseria meningitidis (encapsulated)																						
MP mcr-1	Proteus spp.																						
MAP mor-1 Cryptococcus neoformans/gatti 2138 (CTX-M and CTX-M and DAM) Klebsiella preumoniae group Salmonella spp. ADM) Salmonella spp. Staphylococcus lugdunensis CTX-M NDM NDM NDM OXA-48 like NDM OXA-48 like NDM OXA-48 like NDM OXA-48 like NDM Reviewed by: NDM	Stenotrophomonas maltophilia																						
Mort-1 Cryptococcus neoformans/gatti (Cryptococcus neoformans/gatti)	IMP																						
Cryptococcus neoformans/gattii Z138 (CTX-M and CXA-48 like) CXA-48 like) Klebsiella preumoniae group NDM) Z460 (CTX-M and CTX-M and NDM) CTX-M and CTX-M and CTX-M and CTX-M and Salmonella spp. CTX-M and CTX-M and CTX-M and CTX-M and CTX-M and CTX-M and DM a	mcr-1																						
2138 (CTX-M and 2138 (CTX-M and 2138 (CTX-M and 2460 (CTX-M and	Cryptococcus neoformans/gattii																						
Salmonella spp. Staphylococcus lugdunensis CTX-M NDM OXA-48 like Reviewed by:	Klebsiella pneumoniae group																						
Staphylococcus lugdunersis CTX-M NDM OXA-48 like Reviewed by:	Salmonella spp.																						
like wed by:	_																						
48 like ewed by:	CTX-M																						
	NDM																						
	OXA-48 like																						
	Reviewed by:																						

